• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在经济评估中使用特定疾病结局指标的有效性和可行性。

Validity and feasibility of the use of condition-specific outcome measures in economic evaluation.

作者信息

Stolk Elly A, Busschbach Jan J V

机构信息

Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.

出版信息

Qual Life Res. 2003 Jun;12(4):363-71. doi: 10.1023/a:1023453405252.

DOI:10.1023/a:1023453405252
PMID:12797709
Abstract

BACKGROUND

Usually, generic questionnaires such as the EQ-5D or Health Utility Index (HUI) are used to obtain utility scores for computing QALYs. Sometimes, however, application of these instruments is not possible, or the responsiveness is doubted. An alternative strategy is to attribute utility scores to health states of a condition-specific outcomes measure (CSOM). We explored the validity and feasibility of this strategy.

RESEARCH DESIGN

Our samples determined utility scores for the health states of the International Index of Erectile Function (IIEF) using time tradeoff (TTO). To reduce costs and time, the general population (n = 169) was interviewed in groups. We tested the validity of the group sessions in students. To test the extent of agreement between values obtained using the group and those obtained through individual administration, 63 students were interviewed individually and 54 in groups.

RESULTS

The utility scores for the disease-specific health states showed good construct validity. Also, the criterion validity of the adapted TTO was confirmed.

DISCUSSION

Disease-specific utility scores can be used in QALY analysis by converting them to a generic scale. Efforts should be undertaken to prevent response spreading. Administrating TTO in groups could reduce the time and costs of TTO administration and render the strategy of determining utilities for condition-specific health states more feasible.

摘要

背景

通常,诸如EQ-5D或健康效用指数(HUI)等通用问卷用于获取效用得分以计算质量调整生命年(QALY)。然而,有时无法应用这些工具,或者其反应度受到质疑。另一种策略是将效用得分赋予特定疾病结局测量(CSOM)的健康状态。我们探讨了该策略的有效性和可行性。

研究设计

我们的样本使用时间权衡法(TTO)确定国际勃起功能指数(IIEF)健康状态的效用得分。为了降低成本和节省时间,对普通人群(n = 169)进行了分组访谈。我们在学生中测试了分组访谈的有效性。为了测试分组获得的值与个体访谈获得的值之间的一致程度,对63名学生进行了个体访谈,54名学生进行了分组访谈。

结果

特定疾病健康状态的效用得分显示出良好的结构效度。此外,经调整的TTO的效标效度得到了证实。

讨论

特定疾病的效用得分可通过将其转换为通用量表用于QALY分析。应努力防止反应扩散。分组进行TTO可以减少TTO管理的时间和成本,并使确定特定疾病健康状态效用的策略更可行。

相似文献

1
Validity and feasibility of the use of condition-specific outcome measures in economic evaluation.在经济评估中使用特定疾病结局指标的有效性和可行性。
Qual Life Res. 2003 Jun;12(4):363-71. doi: 10.1023/a:1023453405252.
2
Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.头颈癌患者健康状态效用测量的比较
JAMA Otolaryngol Head Neck Surg. 2015 Aug;141(8):696-703. doi: 10.1001/jamaoto.2015.1314.
3
Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.评估类风湿关节炎中的效用值:时间权衡法与欧洲五维度健康量表的比较
Arthritis Rheum. 2006 Oct 15;55(5):751-6. doi: 10.1002/art.22226.
4
Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease.两种多属性效用测量方法在慢性阻塞性肺疾病患者中的信度、效度及反应度
Qual Life Res. 1999;8(1-2):45-54. doi: 10.1023/a:1026475531996.
5
QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.糖尿病视网膜病变的 QALY 权重——HUI-3、EQ-5D、EQ-VAS 和 TTO 健康状态评估的比较。
Value Health. 2012 May;15(3):475-84. doi: 10.1016/j.jval.2011.11.031. Epub 2012 Feb 10.
6
Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain.采用 HAQ-DI 估算西班牙类风湿关节炎患者的 HUI-3 和 EQ-5D 效用值。
Value Health. 2011 Jan;14(1):192-200. doi: 10.1016/j.jval.2010.11.001.
7
A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.一项针对精神分裂症患者的研究中SF-6D与EQ-5D效用评分的比较。
J Ment Health Policy Econ. 2009 Mar;12(1):27-31.
8
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.类风湿关节炎中通用间接效用测量方法(健康效用指数2、健康效用指数3、SF-6D和欧洲五维度健康量表)与疾病特异性工具(类风湿关节炎生活质量量表和健康评估问卷)的比较。
Soc Sci Med. 2005 Apr;60(7):1571-82. doi: 10.1016/j.socscimed.2004.08.034.
9
A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.类风湿关节炎患者使用 EQ-5D 和 SF-6D 偏好型通用量表进行效用测量的比较。
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):661-71. Epub 2011 Aug 31.
10
Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.比较三种欧洲国家用 EQ-5D 衡量的人口健康状况的不同评估方法。
Value Health. 2009 Jul-Aug;12(5):750-8. doi: 10.1111/j.1524-4733.2009.00509.x.

引用本文的文献

1
Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.使用基于魁北克乳腺癌或结直肠癌患者偏好的 SF-6Dv2 新效价集的癌症人群规范。
Qual Life Res. 2024 Jun;33(6):1605-1619. doi: 10.1007/s11136-024-03653-9. Epub 2024 Apr 20.
2
EQ-5D-Y-3L and EQ-5D-Y-5L proxy report: psychometric performance and agreement with self-report.EQ-5D-Y-3L 和 EQ-5D-Y-5L 代理报告:心理测量性能和与自我报告的一致性。
Health Qual Life Outcomes. 2022 Jun 3;20(1):88. doi: 10.1186/s12955-022-01996-w.
3
Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients.

本文引用的文献

1
A proposal to solve the comparability problem in cost-utility analysis.
J Health Econ. 2002 May;21(3):397-403. doi: 10.1016/s0167-6296(01)00136-9.
2
Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D.通过应用欧洲五维健康量表(EuroQol EQ-5D)估计健康描述与健康估值之间的参数关系。
J Health Econ. 1999 Oct;18(5):551-71. doi: 10.1016/s0167-6296(99)00008-9.
3
EuroQol: the current state of play.欧洲生活质量量表:当前进展情况
比较 EQ-5D-Y-3L 和 EQ-5D-Y-5L 在儿科患者中的测量性能。
Health Qual Life Outcomes. 2021 Nov 15;19(1):256. doi: 10.1186/s12955-021-01889-4.
4
Dimensions Used in Instruments for QALY Calculation: A Systematic Review.用于计算 QALY 的工具中使用的维度:系统评价。
Int J Environ Res Public Health. 2021 Apr 21;18(9):4428. doi: 10.3390/ijerph18094428.
5
Utility Values for the CP-6D, a Cerebral Palsy-Specific Multi-Attribute Utility Instrument, Using a Discrete Choice Experiment.CP-6D 效用值:基于离散选择实验的脑瘫专用多维效用工具
Patient. 2021 Jan;14(1):129-138. doi: 10.1007/s40271-020-00468-x. Epub 2020 Oct 19.
6
Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia.米拉贝隆与抗毒蕈碱药物治疗哥伦比亚成人膀胱过度活动症的成本效益比较
Pharmacoecon Open. 2020 Mar;4(1):79-90. doi: 10.1007/s41669-019-0149-9.
7
The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.条件特异性偏好测量在卫生技术评估中的作用。
Pharmacoeconomics. 2017 Dec;35(Suppl 1):33-41. doi: 10.1007/s40273-017-0546-9.
8
SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration.基于年龄相关性黄斑变性患者的斯内伦等效值,健康状态下较好视力眼和较差视力眼的SF-6D效用值。
PLoS One. 2017 Feb 22;12(2):e0169816. doi: 10.1371/journal.pone.0169816. eCollection 2017.
9
Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.肿瘤学中特定疾病或通用的基于偏好的测量方法?欧洲癌症研究与治疗组织8维度健康状况量表(EORTC - 8D)与欧洲五维度健康量表3级版本(EQ - 5D - 3L)的比较
Qual Life Res. 2017 May;26(5):1163-1176. doi: 10.1007/s11136-016-1443-y. Epub 2016 Nov 9.
10
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.在多发性硬化症马尔可夫模型中使用EQ-5D替代方案对增量成本效益比的影响
Pharmacoeconomics. 2016 Nov;34(11):1133-1144. doi: 10.1007/s40273-016-0421-0.
Health Policy. 1996 Jul;37(1):53-72. doi: 10.1016/0168-8510(96)00822-6.
4
Cost utility of chemotherapy and best supportive care in non-small cell lung cancer.非小细胞肺癌化疗与最佳支持治疗的成本效用
Pharmacoeconomics. 1995 Oct;8(4):316-23. doi: 10.2165/00019053-199508040-00006.
5
Toward consistency in cost-utility analyses: using national measures to create condition-specific values.迈向成本效用分析的一致性:使用国家措施来创建特定疾病的价值。
Med Care. 1998 Jun;36(6):778-92. doi: 10.1097/00005650-199806000-00002.
6
Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.口服西地那非治疗勃起功能障碍。西地那非研究小组。
N Engl J Med. 1998 May 14;338(20):1397-404. doi: 10.1056/NEJM199805143382001.
7
Health values of hospitalized patients 80 years or older. HELP Investigators. Hospitalized Elderly Longitudinal Project.80岁及以上住院患者的健康价值观。HELP研究人员。住院老年人纵向项目。
JAMA. 1998 Feb 4;279(5):371-5. doi: 10.1001/jama.279.5.371.
8
Assessment of patient preferences among men with prostate cancer.
J Urol. 1998 Jan;159(1):158-63. doi: 10.1016/s0022-5347(01)64043-6.
9
Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.
Med Decis Making. 1997 Jul-Sep;17(3):276-84. doi: 10.1177/0272989X9701700303.
10
The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.国际勃起功能指数(IIEF):一种评估勃起功能障碍的多维量表。
Urology. 1997 Jun;49(6):822-30. doi: 10.1016/s0090-4295(97)00238-0.